Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results